Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2012
Accounting Basis: International Financial Reporting Standards (IFRS)
Currency: Danish Kroner (DKK)
Novo Nordisk is a global healthcare company and a world leader in diabetes care, with additional leading positions in haemophilia care, growth hormone therapy, and hormone replacement therapy. The company operates in two segments: Diabetes Care and Biopharmaceuticals. It employs over 35,000 people in 75 countries and markets products in 180 countries.
Key Financial Metrics (2012)
| Metric | 2012 (DKK Millions) | 2011 (DKK Millions) |
|---|---|---|
| Net Sales | 78,026 | 66,346 |
| Operating Profit | 29,474 | 22,374 |
| Net Profit | 21,432 | 17,097 |
| Earnings Per Share (Basic) | 39.09 | 30.24 |
| Free Cash Flow | 18,645 | 18,112 |
| Net Cash from Operating Activities | 22,214 | 21,374 |
| Total Assets | 65,669 | 64,698 |
| Net Assets (Equity) | 40,632 | 37,448 |
| Capital Expenditure | 3,300 | 3,000 |
| R&D Expenses | 10,900 (14.0% of sales) | 9,600 (14.5% of sales) |
Dividends: Proposed dividend of DKK 18.00 per share (45% payout ratio).
Share Repurchases: Completed a DKK 12 billion repurchase program in January 2013, buying 13,057,417 shares in 2012.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17.6% to DKK 78.0 billion, driven by volume growth, new product launches (specifically Victoza), and favorable exchange rates.
- Profitability: Operating profit rose 31.7% to DKK 29.5 billion, and net profit increased 25.4% to DKK 21.4 billion.
- Patent Expirations: The drug compound patent for NovoLog/NovoRapid expired in Japan (2010) and Europe (2011), though formulation patents provide coverage until 2017. Generic competition significantly reduced European sales of Prandin/NovoNorm.
- Capital Structure: The company reduced its share capital by canceling 20 million shares in April 2012 following a repurchase program.
Outlook, Risks, and Management Commentary
Guidance and Outlook
Management expects R&D spending to remain at 14-15% of sales. Capital expenditure for 2013 is expected to be approximately DKK 3.5 billion, focused on expanding production for GLP-1 and devices in Denmark and the U.S., and new facilities in Russia and China. The company anticipates continued growth in the diabetes care segment due to demographic shifts and the transition from human to modern insulins.
Key Risks and Contingencies
- Regulatory: Received an FDA Warning Letter in December 2012 regarding an aseptic filling facility in Denmark; management does not expect this to impact currently marketed U.S. products.
- Patent Expiry: Upcoming patent expirations for key products (NovoLog Mix, NovoSeven) pose risks, though formulation patents and biosimilar complexity are expected to mitigate near-term impacts.
- Legal Proceedings: A U.S. patent appeal regarding Prandin/NovoNorm combination therapy is pending a decision from the Federal Circuit in the first half of 2013.
- Iran Activities: The company conducts business in Iran (gross revenue < DKK 400 million in 2012) involving sales of pharmaceuticals and a contract for a plasma fractionation plant. All payments are routed through non-sanctioned banks.
- Market Risks: Significant exposure to foreign exchange rates (USD, JPY, CNY, GBP) and pricing pressure in key markets due to austerity measures.
Investor Verification Checklist
- Patent Protection Status: Verify the specific expiration dates of formulation patents for NovoLog/NovoRapid and NovoSeven to assess long-term competitive moats.
- FDA Warning Letter Impact: Monitor the resolution of the December 2012 FDA Warning Letter to ensure no future production restrictions or recalls occur.
- Iran Sanctions Compliance: Review ongoing disclosures regarding transactions with the Government of Iran to ensure continued compliance with U.S. sanctions regulations.
- Generic Competition: Track the erosion of Prandin/NovoNorm sales in Europe and the potential impact of the U.S. patent appeal decision on U.S. sales.
- Capital Allocation: Confirm the execution of the DKK 3.5 billion capital expenditure plan for 2013 and the timeline for new facility openings in Russia and China.